- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04629677
Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers
Prospective Evaluation of Portal Vein (PV) Stenting in Patients With PV Stenosis and Gastrointestinal Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To evaluate the safety and efficacy of portal vein stenting in patients with portal vein (PV) stenosis and gastrointestinal malignancies, including quality of life measurements.
SECONDARY OBJECTIVES:
I. Stent patency and duration of clinical success related to the intervention. II. Compare the efficacy of portal vein stenting on liver volumes, nutritional status, and laboratory values relative to patients with portal vein stenosis/thrombosis who do not undergo portal vein stenting.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT A: Patients complete a quality of life (QoL) questionnaire at 2-4 weeks and then 6-8 weeks after portal vein stenting procedure. Patients' medical records are also reviewed.
COHORT B: Patients' medical records are reviewed retrospectively.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Joshua D. Kuban
- Phone Number: 713-745-0944
- Email: jdkuban@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- Joshua D. Kuban
- Phone Number: 713-745-0944
-
Principal Investigator:
- Joshua D. Kuban
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
COHORT A: All patients will undergo initial staging and treatment as per the institution standard of care. Patients will be considered eligible for porto-mesenteric venous stenting (PVS) if:
- There is > 75% porto-mesenteric venous stenosis in either main portal vein (PV), left PV, right PV, or the superior mesenteric vein (SMV), even in absence of symptoms of portal hypertension
- Patients presented with any degree of vascular narrowing of said vessels and symptomatic portal hypertension including variceal bleeding, refractory ascites, abdominal pain, intestinal edema, or diarrhea after exclusion of tumor-related causes as direct tumor invasion or peritoneal dissemination
- COHORT B: Patients who have thrombosis/stenosis of the main portal vein but who did not undergo stenting
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort A (questionnaire, medical record review)
Patients complete a QoL questionnaire at 2-4 weeks and then 6-8 weeks after portal vein stenting procedure.
Patients' medical records are also reviewed.
|
Ancillary studies
Other Names:
Complete questionnaires
Review of medical records
|
Cohort B (medical record review)
Patients' medical records are reviewed retrospectively.
|
Review of medical records
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patency rate (Cohort A)
Time Frame: Up to 8 weeks after stent placement
|
Defined by successful stent placement and described as N (%) of patients with corresponding exact 95% confidence interval.
|
Up to 8 weeks after stent placement
|
Transfusion rate (Cohort A)
Time Frame: Up to 8 weeks after stent placement
|
N (%) of patients receiving transfusion with corresponding exact 95% confidence interval.
Instances of multiple transfusions per patient will also be described.
|
Up to 8 weeks after stent placement
|
Rate of paracenteses for ascites (Cohort A)
Time Frame: Up to 8 weeks after stent placement
|
N (%) of patients receiving paracenteses with corresponding exact 95% confidence interval.
Instances of multiple paracenteses per patient will also be described.
|
Up to 8 weeks after stent placement
|
Duration of clinical success (Cohort A)
Time Frame: Up to 8 weeks after stent placement
|
Mean, median, standard deviation, and minimum/maximum values will be described.
|
Up to 8 weeks after stent placement
|
Change in nutritional status (Cohort A)
Time Frame: Baseline up to 30 days post procedure
|
Based on albumin, pre-albumin, weight, body fat, and body surface area (BSA).
Methods such as repeated measures analysis of variance (ANOVA) with post-hoc Tukey test and generalized estimating equations (GEE) will be used to assess pre- and post- differences.
|
Baseline up to 30 days post procedure
|
Change in bleeding risk (Cohort A)
Time Frame: Baseline up to 30 days post procedure
|
Based on platelet count and coagulation factors.
Methods such as repeated measures ANOVA with post-hoc Tukey test and GEE will be used to assess pre- and post- differences.
|
Baseline up to 30 days post procedure
|
Change in liver function (Cohort A)
Time Frame: Baseline up to 30 days post procedure
|
Methods such as repeated measures ANOVA with post-hoc Tukey test and GEE will be used to assess pre- and post- differences.
|
Baseline up to 30 days post procedure
|
Change in liver volume (Cohort A)
Time Frame: Baseline up to 30 days post procedure
|
Methods such as repeated measures ANOVA with post-hoc Tukey test and GEE will be used to assess pre- and post- differences.
|
Baseline up to 30 days post procedure
|
Change in quality of life (QoL) (Cohort A)
Time Frame: Baseline up to 30 days post procedure
|
Will be assessed based on National Comprehensive Cancer Network - Hepatibiliary Symptom Index Questionnaire - 18 item.
Methods such as repeated measures ANOVA with post-hoc Tukey test and GEE will be used to assess pre- and post- differences.
For QoL will also present effect size, defined as the magnitude of the differences in relation to the standard deviation of the scores, which will be reflective of the strength of the effect of portal stenting on QoL.
|
Baseline up to 30 days post procedure
|
Number of transfusions (Cohort A and B)
Time Frame: Up to 8 weeks post procedure
|
Methods such as paired t-tests, conditional logistic regression, and generalized linear modeling will be used to compare differences by cohort.
|
Up to 8 weeks post procedure
|
Number of paracentesis for ascites (Cohort A and B)
Time Frame: Up to 8 weeks post procedure
|
Methods such as paired t-tests, conditional logistic regression, and generalized linear modeling will be used to compare differences by cohort.
|
Up to 8 weeks post procedure
|
Liver volume (Cohort A and B)
Time Frame: Up to 8 weeks post procedure
|
Methods such as paired t-tests, conditional logistic regression, and generalized linear modeling will be used to compare differences by cohort.
|
Up to 8 weeks post procedure
|
Liver function (Cohort A and B)
Time Frame: Up to 8 weeks post procedure
|
Methods such as paired t-tests, conditional logistic regression, and generalized linear modeling will be used to compare differences by cohort.
|
Up to 8 weeks post procedure
|
Nutritional status (Cohort A and B)
Time Frame: Up to 8 weeks post procedure
|
Based on albumin, pre-albumin, weight, body fat, and BSA.
Methods such as paired t-tests, conditional logistic regression, and generalized linear modeling will be used to compare differences by cohort.
|
Up to 8 weeks post procedure
|
Bleeding risk (Cohort A and B)
Time Frame: Up to 8 weeks post procedure
|
Based on platelet count and coagulation factors.
Methods such as paired t-tests, conditional logistic regression, and generalized linear modeling will be used to compare differences by cohort.
|
Up to 8 weeks post procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joshua D Kuban, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PA18-0712 (Other Identifier: M D Anderson Cancer Center)
- NCI-2020-07171 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Digestive System Neoplasm
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMalignant Gastrointestinal Neoplasm | Malignant Peritoneal NeoplasmUnited States
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedSecondary Malignant Neoplasm of LiverChina
-
Istituto Clinico HumanitasTerminatedSecondary Malignant Neoplasm of LiverItaly
-
University of MilanCompletedSecondary Malignant Neoplasm of LiverItaly
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Solid Neoplasm | Breast Carcinoma | Digestive System Neoplasm | Skin Carcinoma | Malignant Female Reproductive System Neoplasm | Metastatic Malignant Neoplasm of Unknown Primary | Malignant Head and Neck Neoplasm | Malignant Brain Neoplasm | Malignant Central Nervous System Neoplasm | Malignant... and other conditionsUnited States
-
Medical University of GrazCompleted
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Second Affiliated Hospital...RecruitingSecondary Malignant Neoplasm of LiverChina
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingColon Cancer | Malignant Neoplasm | Colon Neoplasm, Malignant | Colon Neoplasm | Colon NeoplasiaSpain
-
M.D. Anderson Cancer CenterNational Institute of Nursing Research (NINR)Active, not recruitingAdvanced Malignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditionsUnited States